Get the Stockscreener App
1.69
4.52%
-0.08
After Hours:
1.68
-0.01
-0.59%
Alzamend Neuro Inc stock is traded at $1.69, with a volume of 180.01K.
It is down -4.52% in the last 24 hours and down -28.09% over the past month.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
See More
Previous Close:
$1.77
Open:
$1.76
24h Volume:
180.01K
Relative Volume:
0.11
Market Cap:
$6.52M
Revenue:
-
Net Income/Loss:
$-12.40M
P/E Ratio:
-10.56
EPS:
-0.16
Net Cash Flow:
$-9.08M
1W Performance:
+9.03%
1M Performance:
-28.09%
6M Performance:
-83.10%
1Y Performance:
-28.69%
1-Day Range:
$1.62
$1.80
1-Week Range:
$1.50
$1.80
52-Week Range:
$1.132
$20.32
Alzamend Neuro Inc Stock (ALZN) Company Profile
Name
Alzamend Neuro Inc
Sector
Industry
Phone
844-722-6333
Address
3500 LENOX RD. NE, ATLANTA
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-21 | Initiated | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Stock (ALZN) Latest News
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session - MSN
A Guide To The Risks Of Investing In Alzamend Neuro Inc (ALZN) - Knox Daily
Alzamend Neuro Inc: Rising -96.02% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Alzamend Neuro stock hits 52-week low at $1.81 amid market challenges - Investing.com
Alzamend Neuro stock hits 52-week low at $1.81 amid market challenges - Investing.com India
Understanding the Risks of Investing in Alzamend Neuro Inc (ALZN) - Knox Daily
Ratios Reveal: Breaking Down Alzamend Neuro Inc (ALZN)’s Financial Health - The Dwinnex
Keeping an Eye on Alzamend Neuro Inc (ALZN) After Insider Trading Activity - Knox Daily
Alzamend Neuro Inc (ALZN) is a good investment, but the stock may be overvalued - US Post News
Alzamend Neuro Inc [ALZN] Records 50-Day SMA of $3.50 - Knox Daily
It is Poised to be a Bull Market for Alzamend Neuro Inc (ALZN) - SETE News
Investing in Alzamend Neuro Inc (ALZN): What You Must Know - Knox Daily
Market Momentum: Alzamend Neuro Inc (ALZN) Registers a -7.47 Decrease, Closing at 2.85 - The Dwinnex
Alzamend partners with Mass General for clinical trials - Investing.com
Examining Alzamend Neuro Inc (ALZN) more closely is necessary - US Post News
Alzamend partners with Mass General for clinical trials By Investing.com - Investing.com UK
Alzamend Neuro Issues Letter to Stockholders - StockTitan
ALZN Stock Sees Surge of Approximately 72.96% in Last Five Days - Knox Daily
Daily Market Movement: Alzamend Neuro Inc (ALZN) Sees a -0.91 Decrease, Closing at 4.35 - The Dwinnex
Get in on Alzamend Neuro Inc’s (ALZN) buy-in window today! - SETE News
Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board - Quantisnow
A Guide To The Risks Of Investing In Alzamend Neuro Inc (ALZN) - Knoxdaily.com
Alzamend Neuro Inc [ALZN] Stock trading around $5.85 per share: What’s Next? - The DBT News
Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher - MSN
Nvidia, AMD, Alzamend Neuro, Palo Alto Networks, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder - Quantisnow
Analyzing the Impact of Earnings Reports on Alzamend Neuro Inc Inc. (ALZN) Price Performance - The InvestChronicle
Nasdaq Surges 150 Points; Sonder Holdings Shares Surge - Benzinga
Alzamend Neuro (ALZN) Could Triple from current levels and here’w why - BP Journal
Crude Oil Down 2%; Alzamend Neuro Shares Spike Higher - Benzinga
Alzamend Neuro Shares Rise on Partnership for PTSD Treatment Mid-Stage Study - MarketWatch
Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details - Benzinga
Alzamend Neuro begins phase II PTSD treatment study - Investing.com
Alzamend Neuro begins phase II PTSD treatment study By Investing.com - Investing.com Australia
Alzamend Neuro begins phase II PTSD treatment study By Investing.com - Investing.com UK
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder - Chronicle-Tribune
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder - Business Wire
Alzamend Neuro Receives FDA “Study May Proceed” Notification for - GuruFocus.com
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder - Manchestertimes
Alzamend Neuro director Milton Ault III buys shares worth $206 - Investing.com India
Alzamend Neuro director Milton Ault III buys shares worth $206 By Investing.com - Investing.com South Africa
Alzamend Neuro stock hits 52-week low at $1.95 amid steep decline - Investing.com Australia
Alzamend Neuro director Milton Ault III buys shares worth $206 - Investing.com
Alzamend Neuro stock hits 52-week low at $1.95 amid steep decline - Investing.com India
Alzamend Neuro stock hits 52-week low at $1.95 amid steep decline - Investing.com UK
Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Large Increase in Short Interest - Defense World
ALZNAlzamend Neuro, Inc. Latest Stock News & Market Updates - StockTitan
Alzamend Neuro and Massachusetts General Hospital Collaborate on Phase II Trial for Major Depressive Disorder Treatment - Vancity Buzz
Neurocrine Bioscienc (NBIX-Q) QuotePress Release - The Globe and Mail
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder | FinancialContent Business Page - Financial Content
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder - Marketscreener.com
Alzamend Neuro Inc Stock (ALZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):